Subramanian Sankar - 09 Jun 2021 Form 3 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Senior VP, Product Development
Signature
/s/ Anna Mowry, as Attorney-in-Fact
Issuer symbol
NAUT
Transactions as of
09 Jun 2021
Net transactions value
$0
Form type
3
Filing time
09 Jun 2021, 21:39:00 UTC
Next filing
25 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NAUT Stock Option (Right to Buy) 09 Jun 2021 Common Stock 725,614 $1.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, 13/49ths of the shares subject to the Option shall vest on the thirteen (13) month anniversary of the Vesting Commencement Date (as defined below), and one forty-ninth (1/49th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month).The Vesting Commencement Date is December 3, 2020.

Remarks:

Exhibit 24: Power of Attorney